- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06340646
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Study Overview
Status
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Graham Colditz, M.D., DrPH, MPH
- Phone Number: 314-454-7939
- Email: colditzg@wustl.edu
Study Contact Backup
- Name: Bettina Drake, Ph.D., MPH
- Phone Number: 314-747-4534
- Email: drakeb@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Sub-Investigator:
- Eric Duncavage, M.D.
-
Sub-Investigator:
- Kian-Huat Lim, M.D., Ph.D.
-
Sub-Investigator:
- Fei Wan, Ph.D.
-
Sub-Investigator:
- Mary Politi, Ph.D.
-
Sub-Investigator:
- Ryan Fields, M.D.
-
Sub-Investigator:
- Li Ding, Ph.D.
-
Sub-Investigator:
- David Spencer, M.D., Ph.D.
-
Sub-Investigator:
- Mark Watson, M.D., Ph.D.
-
Contact:
- Graham Colditz, M.D., DrPH, MPH
- Phone Number: 314-454-7939
- Email: colditzg@wustl.edu
-
Contact:
- Bettina Drake, Ph.D., MPH
- Phone Number: 314-747-4534
- Email: drakeb@wustl.edu
-
Principal Investigator:
- Graham Colditz, M.D., DrPH, MPH
-
Sub-Investigator:
- Bettina Drake, Ph.D.
-
Sub-Investigator:
- Yin Cao, ScD, MPH
-
Sub-Investigator:
- Feng Chen, Ph.D.
-
Sub-Investigator:
- Kia Davis, ScD, MPH
-
Sub-Investigator:
- Patricia Dickson, M.D.
-
Sub-Investigator:
- Mark Fiala, MSW
-
Sub-Investigator:
- Aimee James, Ph.D., MPH
-
Sub-Investigator:
- Reyka Jayasinge, Ph.D.
-
Sub-Investigator:
- Erin Linnenbringer, Ph.D., MS
-
Sub-Investigator:
- Jessica Mozersky, Ph.D.
-
Sub-Investigator:
- Tunji Toriola, M.D., Ph.D., MPH
-
Sub-Investigator:
- Ravi Vij, M.D., MBA
-
Sub-Investigator:
- Mike Wendl, DSC, MS, PHS
-
Sub-Investigator:
- Matthew Wyczalkowsi, Ph.D.
-
Sub-Investigator:
- Stephanie Solomon Cargill, Ph.D., MSPH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Eligibility Criteria:
Patients with cholangiocarcinoma, multiple myeloma, or early onset colon or rectal cancer.
- If diagnosed with multiple myeloma, must be African-American.
- If diagnosed with colon or rectal cancer, must be African-American AND must be no older than 50 years old.
- At least 18 years old
- Able to understand and willing to sign an IRB-approved written informed consent document
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No Return of Genetic Results
Participants will undergo germline genomic sequencing as part of consenting to the WU-PE-CGS program. Participants will be given the option to receive the results from the genomic sequencing. After they consent to the study, the types of results available to them will be explained by research staff. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues. These choices will be presented to them via a discussion with study staff with accompanying paper information |
|
Experimental: Return of Genetic Results
Participants will undergo germline genomic sequencing as part of consenting to the WU-PE-CGS program. Participants will be given the option to receive the results from the genomic sequencing. After they consent to the study, the types of results available to them will be explained by research staff. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues. These choices will be presented to them via a discussion with study staff with accompanying paper information |
Participants will receive a novel return of results report that is tailored to their choices.
Participants will receive a novel return of results report that is tailored to their choices.
Participants will receive a novel return of results report that is tailored to their choices.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant knowledge of clinical genetic testing
Time Frame: 6-8 weeks after results have been received and one year after disclosure of results
|
11-item, Likert scale.
This scale has 5 points ranging from strongly agree to strongly disagree.
1=Strongly Agree, 2=Agree, 3=Neither Agree nor Disagree, 4=Disagree, 5=Strongly Disagree for items (4, 6-11) are scored such that 'strong disagree' reflects a correct response and 'somewhat disagree' reflects a less confident correct response in the correct direction.
Negatively worded items (items 1, 2, 3, and 5) are reverse scored so that 'strongly agree' reflects a correct response and 'somewhat agree' reflect a less confident response in the correct direction.
This will be scored by adding up the numbers for each of the 11 items regarding participant knowledge of clinical genetic testing.
The total score ranges from 5 to 55.
A higher score for the participant represents higher participant knowledge.
|
6-8 weeks after results have been received and one year after disclosure of results
|
Participant expectations of benefit
Time Frame: 6-8 weeks after results have been received and one year after disclosure of results
|
Participants will rate their expectation for 6 potential benefits of cancer genomic sequencing on a 4-point scale ranging from extremely unlikely to extremely likely. .
1=Strongly Agree, 2=Agree, 3=Disagree, 4=Strongly Disagree.
This will be scored by adding up the numbers for each of the 8 items regarding participant expectations of benefit.
The total score ranges from 6 to 24.
A higher score for the participant represents higher levels of expectations.
|
6-8 weeks after results have been received and one year after disclosure of results
|
Participant personal utility
Time Frame: 6-8 weeks after results have been received and one year after disclosure of results
|
Participant personal utility will be measured on a 7-point scale ranging from not at all useful to extremely useful.
1=Not at all useful, 2=A little useful, 3=Somewhat useful, 4=Neutral, 5=Useful, 6=Very useful, 7=Extremely useful.
This will be scored by adding up the numbers for each of the 14 items regarding participant personal utility.
The total score ranges from 14 to 98.
A higher score for the participant represents higher personal utility.
|
6-8 weeks after results have been received and one year after disclosure of results
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant anxiety
Time Frame: Baseline, 6-8 weeks after results have been received, and one year after disclosure of results
|
Participant anxiety will be measured using a 5-point Likert scale ranging from not at all to very much.
0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much.
This will be scored by adding up the numbers for each of the 6 items regarding participant cancer worry.
The total score ranges from 0 to 24.
A higher score for the participant represents higher participant cancer worry.
|
Baseline, 6-8 weeks after results have been received, and one year after disclosure of results
|
Participant satisfaction
Time Frame: Baseline, 6-8 weeks after results have been received, and one year after disclosure of results
|
Satisfaction will be measured using a 5-point Likert scale ranging from extremely satisfied to not at all.
1=Not at all satisfied, 2=A little bit, 3=Somewhat, 4=Quite a bit, 5=Extremely satisfied.
The total score ranges from 1 to 5. A higher score for the participant represents higher participant satisfaction.
|
Baseline, 6-8 weeks after results have been received, and one year after disclosure of results
|
Collaborators and Investigators
Investigators
- Principal Investigator: Graham Colditz, M.D., DrPH, MPH, Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Multiple Myeloma
- Cholangiocarcinoma
Other Study ID Numbers
- 202106129
- U2CCA252981 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Will share all data, software and know-how generated during the course of this work, without limitations except as prevented by prior agreement. This will include both the final datasets, as well as the data necessary to complete the aims. Will disseminate results from this research through presentations at public lectures, scientific institutions and meetings, and/or publication in major journals. All final peer-reviewed manuscripts that arise from this proposal will be submitted to the digital archive PubMed Central. Wherever applicable, data will be deposited to appropriate public repositories.
All participants whose genomic data are collected will be consented for broad data sharing, and their genomic data will be included in the study deposits. Data documentation and de-identified data will be deposited for sharing along with phenotypic data, which includes demographics and diagnosis, consistent with applicable laws and regulations.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Return of Genetic Results: Biomarker information from cancer cells
-
Boston Children's HospitalActive, not recruitingDisorders of Sex Development | HypospadiasUnited States
-
Institute of Cancer Research, United KingdomCancer Research UK; University of Manchester; University of SussexCompletedBreast Neoplasm FemaleUnited Kingdom
-
Fred Hutchinson Cancer CenterHighPass Bio, Inc.SuspendedAcute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedObesity | Uterine Cancer | Stage I Endometrial AdenocarcinomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); EMD SeronoTerminatedStage IV Merkel Cell Carcinoma AJCC v7 | Merkel Cell Polyomavirus InfectionUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma | Stage IB Esophageal Adenocarcinoma | Stage IIA Esophageal AdenocarcinomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLCTerminatedAdult GlioblastomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Stage II Pancreatic Cancer AJCC v6 and v7 | Stage IIA Pancreatic Cancer AJCC v6 and v7 | Stage IIB Pancreatic Cancer AJCC v6 and...United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Merkel Cell Carcinoma | Stage IV Merkel Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupTerminatedRecurrent Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma AJCC v7 | Stage II Adult Soft Tissue Sarcoma AJCC v7 | Stage III Adult Soft Tissue Sarcoma AJCC v7United States